Literature DB >> 9650537

Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers.

M N Gharaibeh1, L P Gillen, B Osborne, J I Schwartz, S A Waldman.   

Abstract

The erythromycin breath test (EBT), which measures 14CO2 produced from [14C N-methyl] erythromycin, is one of the most frequently employed measures to examine drug interactions involving cytochrome P450 3A4 (CYP3A). However, the reproducibility and reliability of this test, and the effects of drugs that alter CYP3A activity, continue to be defined. In this study, the reproducibility of the EBT was evaluated in eight healthy volunteers before and after oral administration of 600 mg of rifampin daily for 8 days. Two sequential EBT determinations performed 5 days apart before rifampin administration were highly reproducible. Rifampin induced CYP3A, reflected in a mean percent (+/- standard deviation) increase in EBT values of 86 +/- 30%. Recovery of enzyme function after discontinuation of rifampin for 17 days was manifested as a return of EBT values to preinduction levels. These results support the utility of EBT as a valid, reproducible, and reliable measure of CYP3A activity in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9650537     DOI: 10.1002/j.1552-4604.1998.tb05785.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

Review 1.  The erythromycin breath test for the prediction of drug clearance.

Authors:  L P Rivory; K A Slaviero; J M Hoskins; S J Clarke
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.

Authors:  Patrick J Roberts; Kristan D Rollins; Angela D M Kashuba; Mary F Paine; Andrew C Nelsen; Eric E Williams; Cassandra Moran; Jatinder K Lamba; Erin G Schuetz; Roy L Hawke
Journal:  Drug Metab Dispos       Date:  2008-05-19       Impact factor: 3.922

4.  Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.

Authors:  R E Polk; D F Brophy; D S Israel; R Patron; B M Sadler; G E Chittick; W T Symonds; Y Lou; D Kristoff; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

5.  Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.

Authors:  Stéphane Mouly; Nathalie Rizzo-Padoin; Guy Simoneau; Céline Verstuyft; Guy Aymard; Cécile Salvat; Isabelle Mahé; Jean-François Bergmann
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

Review 6.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Breath tests to phenotype drug disposition in oncology.

Authors:  Frans L Opdam; Anil S Modak; Hans Gelderblom; Henk-Jan Guchelaar
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

Review 8.  Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4.

Authors:  Stéphane Mouly; Christophe Meune; Jean-François Bergmann
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.